Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 1
2007 2
2009 2
2010 2
2011 4
2012 4
2013 4
2014 4
2015 3
2016 7
2017 4
2018 7
2019 3
2020 10
2021 6
2022 6
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hodgkin Lymphoma by Clinical Course"
Page 1
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML. Hill HA, et al. Blood Adv. 2020 Jul 14;4(13):2927-2938. doi: 10.1182/bloodadvances.2019001350. Blood Adv. 2020. PMID: 32598477 Free PMC article.
Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. ...Our data also show a change in mutational status from baseline samples to samples at disease progression and …
Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeut …
PET-adapted therapy for advanced Hodgkin lymphoma - systematic review.
Amitai I, Gurion R, Vidal L, Dann EJ, Raanani P, Gafter-Gvili A. Amitai I, et al. Acta Oncol. 2018 Jun;57(6):765-772. doi: 10.1080/0284186X.2018.1426877. Epub 2018 Jan 18. Acta Oncol. 2018. PMID: 29345517 Review.
INTRODUCTION: Positron emission tomography-computed tomography (PET-CT) performed after two chemotherapy cycles (PET-2) has become an accepted prognostic tool in Hodgkin lymphoma (HL). We evaluated the effect of PET-adapted strategy on outcome in advanced stage HL. …
INTRODUCTION: Positron emission tomography-computed tomography (PET-CT) performed after two chemotherapy cycles (PET-2) has become an accept …
Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
Dada R, Zekri J, Al Saadi R. Dada R, et al. Expert Opin Biol Ther. 2016 Jun;16(6):739-45. doi: 10.1080/14712598.2016.1180362. Epub 2016 May 3. Expert Opin Biol Ther. 2016. PMID: 27096887 Review.
OBJECTIVES: This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV) in patients with relapsed/refractory Hodgkin lymphoma (HL). PATIENTS AND METHODS: A systematic literature search was performed and included studies published from 1(st) Janu …
OBJECTIVES: This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV) in patients with relapsed/refractory Hodgkin …
Anaplastic large cell lymphoma and breast implants: a systematic review.
Kim B, Roth C, Chung KC, Young VL, van Busum K, Schnyer C, Mattke S. Kim B, et al. Plast Reconstr Surg. 2011 Jun;127(6):2141-2150. doi: 10.1097/PRS.0b013e3182172418. Plast Reconstr Surg. 2011. PMID: 21358562 Review.
BACKGROUND: In recent years, there have been growing concerns about a possible association of non-Hodgkin's lymphoma--in particular, anaplastic large cell lymphoma (ALCL)--and breast implants. ...Although detailed clinical information was lacking in ma …
BACKGROUND: In recent years, there have been growing concerns about a possible association of non-Hodgkin's lymphoma--in parti …
Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Colosia A, et al. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-355.e6. doi: 10.1016/j.clml.2014.02.012. Epub 2014 Mar 1. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24768510 Review.
This systematic literature review was designed to assess information on the clinical efficacy and safety of interventions used in the treatment of refractory or relapsed diffuse large B-cell lymphoma (R/R DLBCL) and to perform a meta-analysis if possible. ...Studies …
This systematic literature review was designed to assess information on the clinical efficacy and safety of interventions used in the …
Germinotropic lymphoproliferative disorder: a systematic review.
Zanelli M, Zizzo M, Bisagni A, Froio E, De Marco L, Valli R, Filosa A, Luminari S, Martino G, Massaro F, Fratoni S, Ascani S. Zanelli M, et al. Ann Hematol. 2020 Oct;99(10):2243-2253. doi: 10.1007/s00277-020-04024-3. Epub 2020 Apr 19. Ann Hematol. 2020. PMID: 32307569
Human herpesvirus 8 is a lymphotropic virus detected in Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma, Human herpesvirus 8-positive diffuse large B cell lymphoma not otherwise specified, and germinotropic lymphoproliferative disord …
Human herpesvirus 8 is a lymphotropic virus detected in Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma …
Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
Sun C, Chen H, Wang Y, Zheng C. Sun C, et al. Hematology. 2023 Dec;28(1):2181749. doi: 10.1080/16078454.2023.2181749. Hematology. 2023. PMID: 36892260
BACKGROUND: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 i …
BACKGROUND: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment …
PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis.
Sickinger MT, von Tresckow B, Kobe C, Borchmann P, Engert A, Skoetz N. Sickinger MT, et al. Crit Rev Oncol Hematol. 2016 May;101:86-92. doi: 10.1016/j.critrevonc.2016.03.005. Epub 2016 Mar 6. Crit Rev Oncol Hematol. 2016. PMID: 26971064 Review.
BACKGROUND: Hodgkin lymphoma (HL) is one of the most common malignancies in young adults and one of the most curable cancers worldwide. ...Only one trial provided data for OS, without evidence for a difference between both arms (HR 0.51; 95% CI 0.15-1.68). All three …
BACKGROUND: Hodgkin lymphoma (HL) is one of the most common malignancies in young adults and one of the most curable cancers w …
Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review.
Kim JS, Lee KH, Kim GE, Kim S, Yang JW, Li H, Hong SH, Ghayda RA, Kronbichler A, Koyanagi A, Jacob L, Shin JI, Smith L. Kim JS, et al. Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11926-11933. doi: 10.26355/eurrev_202011_23852. Eur Rev Med Pharmacol Sci. 2020. PMID: 33275265 Free article.
OBJECTIVE: Hematologic cancer patients with Coronavirus Disease 2019 (COVID-19) tend to have a more serious disease course than observed in the general population. Herein, we comprehensively reviewed existing literature and analyzed clinical characteri …
OBJECTIVE: Hematologic cancer patients with Coronavirus Disease 2019 (COVID-19) tend to have a more serious disease course …
Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario.
Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR; Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Cheung MC, et al. Cancer Treat Rev. 2007 Apr;33(2):161-76. doi: 10.1016/j.ctrv.2006.10.005. Epub 2007 Jan 22. Cancer Treat Rev. 2007. PMID: 17240533 Review.
We aimed to systematically review the literature on rituximab in non-Hodgkin's lymphoma and provide consensus guidelines as to the rational use of this agent. ...A comprehensive literature search was completed by reviewers from the Hematology Disease Site Gro …
We aimed to systematically review the literature on rituximab in non-Hodgkin's lymphoma and provide consensus guidelines as to …
74 results